Discussion
A multicenter Phase 1/2 clinical trial of a gene therapy for CLN7 Batten disease, a form of late-infantile Batten disease, will soon begin in Canada. The trial is being supported by funding that includes $768,823 CAD ($543,326 USD) from Conscience, a Canadian nonprofit focused on drug discovery.